 There will be two groups to the study. Individuals, aged 18 years or older, who have had a renal transplant but are in otherwise general good health, will be given UAB30 160 mgday and will be compared to individuals, aged 18 years or older, who have had a renal transplant and are in otherwise general good health who are given placebo. All participants must be at increased risk of non-melanoma skin cancer as evidenced by a history of prior squamous or basal cell skin cancer, ongoing or history of actinic keratoses, and the presence, at baseline, of at least eight actinic keratoses on the face, neck, scalp and arms. Subjects will be randomized to 28 days of: 